一级婬片试看120分钟,安徽少妇BBBB搡BBBB,波多野结衣一级片

香蕉91成人一区二区三区飘花,91精品人妻一区二区三区蜜桃,四川少妇BBw搡BBBB槡BBBB,国产成人91一区二区三区APP

<tr id="cc0cc"></tr>

<nav id="cc0cc"></nav><small id="cc0cc"></small>

<sup id="cc0cc"></sup>

CN

CN EN

Latest News

Latest News Media Downloads Video Center

Kexing Biopharm's clinical trial application accepted for human interferon α1b inhalation solution
2022-08-19

2022-08-19

On the evening of August 18, 2022, Kexing Biopharm...
Kexing Biopharm's clinical trial application accepted for another dosage form of human interferon α2b
2022-08-15

2022-08-15

On the evening of August 14, 2022, Kexing Biopharm Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that it had recently received the Notice of Acceptance, an administrative license document issued by the National Medical Products Administration (hereinafter referred to as "NMPA"), indicating that its clinical trial application for "Human Interferon α2b Spray" was accepted.
Kexing Biopharm's clinical trial application accepted for "Pegylated Human Granulocyte Colony-stimulating Factor Injection"
2022-08-02

2022-08-02

On the evening of August 1, 2022, Kexing Biopharm Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that it had just received the Notice of Acceptance, an administrative license document issued by the National Medical Products Administration (hereinafter referred to as "NMPA"), indicating that its clinical trial application for "Pegylated Human Granulocyte Colony-stimulating Factor Injection" was accepted.
Kexing Biopharm's conference for reviewing operation and management in first half of 2022and planning key tasks for the second half-year held successfully
2022-08-01

2022-08-01

In the face of the complicated political and economic environment in China and overseas as well as the tough situation in the pharmaceutical industry, Kexing Biopharm proposed the working policy themed as "intensely licensing in new products, firmly promoting R&D and innovation, and proactively creating business in new industries" at the beginning of the year, and continuously followed and implemented the policy in the first half-year.
Phase I clinical trial kick-off meeting of Kexing Biopharm's COVID-19 oral drug SHEN26 Capsule held successfully
2022-07-22

2022-07-22

On July 20, 2022, the phase I clinical trial kick-off meeting of SHEN26 Capsule, a small-molecule oral drug against COVID-19 jointly developed by Shenzhen Kexing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Kexing Biopharm (688136.SH), and Shenzhen Antiv Pharma Co., Ltd., was successfully held in the Second Affiliated Hospital of Anhui Medical University, indicating the official start of the clinical study for the project.

1 2 3 4 5

Support Hotline

0755-26546500
Online Consultation
QR Code

Scan Code Consultation

国产精品久久久久久一级毛片探花 | 北条麻纪在线观看AⅤ | 一级老太婆毛片免费播放 | 3D动漫精品啪啪一区二区免费 | 国产三级片一区二区三区 | 国产精品高潮呻吟AV无码 | 国产欧美日韩卡一 | 小香蕉啪啪午夜成人AV | 中文字幕免费在线观看 | 欧美久久17c一区二区 | 女人高潮一级一片17 | 四川少妇搡bbbb搡bbbb | 少妇w搡BBB搡BBB出血 | 国产护士囗交吞精视频 | 狠狠色综合7777久夜色撩人 | 少妇搡BBBB搡BBBB毛多多 | 成人纯肉无码在线观看 | 成人免费a片xxx喷 | 国产成人污视频网站 | 男女免费爱爱好爽动态图 | 色综合天天综合网国产成人网 | 少妇搡BBBB搡BBB搡视频一级 | 福利中文弹幕在线观看 | 少妇被大黑捧猛烈进出的 | 久激情内射婷内射蜜桃欧美一级 | the Porn日本在线 | 国产伦精品一区二区三区88AV | 亚洲一区二区中文字幕 | 精品国产乱码一区二区三区 | 中文字幕在线免费观看网站 | 国产一级a毛一级a看免费视频乱 | 久久久国产精品免费A片蜜欧美性猛交 XX 乱下载 | 精品乱子伦一区二区三区 | 中文字幕免费视频在线观看 | 无码内射高潮视频 | 午夜日韩射精福利在线观看 | 精品中文字幕综合 | 素人美女被操到高潮完整版在线观看 | 成人网站在线看污污污污 | 欧美精品无码成人A片九色播放 | 性猛交一级A片少妇视频无码 |

<tfoot id="ccccc"><dd id="ccccc"></dd></tfoot>

<nav id="ccccc"></nav>

<tr id="ccccc"></tr><tr id="ccccc"></tr>

<noscript id="ccccc"><dd id="ccccc"></dd></noscript>